AVTX

Avalo Therapeutics, Inc.

Price Chart

Latest Quote

$15.40

+1.07 (+7.47%)

Current Price

Previous Close	$14.33
Open	$14.41
Day High	$15.50
Day Low	$14.27
Volume	826,533

Fetched: 2026-06-17T18:25:05

Stock Information

Shares Outstanding	52.57M
Total Debt	$328K
Cash Equivalents	$81.99M
Revenue	$59K
Net Income	$-84.74M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$809.51M
EPS (TTM)	$-5.57
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$671.60M
Sales	$59K
Income	$-84.74M
Book/sh	$2.77
Cash/sh	$1.56
Employees	33

Financial Ratios

Quick Ratio	7.07
Current Ratio	7.66
Debt/Eq	0.48

Returns & Margins

ROA	-41.50%
ROE	-88.76%
Operating Margin	-134164.40%

Ownership

Insider Ownership	1.73%
Institutional Ownership	74.94%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-5.50
P/S	13720.50
P/B	5.55

Analyst Data

Recommendation	strong_buy
Target Price	$45.25

Technical Indicators

SMA20	$14.74
SMA50	$15.43
SMA200	$15.53
RSI	44.72
ATR	0.9638

Shares Float	40.25M
Short Float	12.16%
Short Ratio	2.34
Volatility	0.82
Rel Volume	0.62

Performance History

Week	+17.56%
Month	-4.70%
Quarter	+4.90%
6 Months	-12.99%
YTD	-9.52%
Year	+234.06%
3 Years	-98.45%
5 Years	-99.85%
10 Years	-99.79%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-17	$15.40	826,533
2026-06-16	$14.33	1,543,500
2026-06-15	$14.60	950,300
2026-06-12	$14.76	1,120,500
2026-06-11	$13.67	817,300
2026-06-10	$13.10	1,635,200
2026-06-09	$12.90	1,296,500
2026-06-08	$12.74	1,044,900
2026-06-05	$13.10	1,757,700
2026-06-04	$13.61	1,353,600
2026-06-03	$13.74	2,515,400
2026-06-02	$13.96	1,604,200
2026-06-01	$15.75	824,000
2026-05-29	$15.95	1,075,700
2026-05-28	$16.13	1,738,300
2026-05-27	$15.79	972,000
2026-05-26	$16.02	1,381,400
2026-05-22	$16.35	1,317,200
2026-05-21	$16.60	1,363,600
2026-05-20	$16.29	1,316,600
2026-05-19	$16.27	1,671,000
2026-05-18	$16.16	2,542,100

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

📰 Latest News

Sector Update: Healthcare Stocks Softer Late Afternoon

MT Newswires • 2026-06-12T19:40:04Z

This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout

Investor's Business Daily • 2026-05-06T20:07:15Z

Avalo shares spike on skin drug data; BioNTech to cut staff

BioPharma Dive • 2026-05-06T10:30:00Z

Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics

Zacks • 2026-04-06T15:10:00Z

Avalo Therapeutics (NASDAQ:AVTX) Is In A Good Position To Deliver On Growth Plans

Simply Wall St. • 2026-04-06T12:49:46Z

Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More

24/7 Wall St. • 2026-04-06T11:54:28Z

Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know

Zacks • 2026-04-03T13:55:02Z

5 Small Drug Stocks to Buy as Sector Recovery Gains Strength

Zacks • 2026-04-02T14:00:00Z

CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer

Zacks • 2026-03-26T15:53:00Z

Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference

MarketBeat • 2026-03-12T13:53:32Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$0	$-366,000	$1,284,000	$3,306,000
Cost Of Revenue	$0	$-366,000	$1,284,000	$3,434,000
Total Revenue	$59,000	$441,000	$1,924,000	$18,051,000
Operating Revenue	$59,000	$441,000	$1,924,000	$18,051,000
Expenses
Total Expenses	$72,984,000	$41,312,000	$25,368,000	$55,491,000
Other Income Expense	$-9,520,000	$2,544,000	$-4,669,000	$-20,000
Net Non Operating Interest Income Expense	$4,351,000	$3,312,000	$-3,417,000	$-4,170,000
Total Other Finance Cost	$-4,351,000	$-3,312,000	$3,417,000	$4,170,000
Operating Expense	$72,984,000	$41,678,000	$24,084,000	$52,057,000
Selling And Marketing Expense	$470,000	$789,000	$33,000	$76,000
General And Administrative Expense	$22,430,000	$16,452,000	$10,267,000	$20,635,000
Interest Expense	-	$-3,317,000	$3,417,000	$4,170,000
Other Non Operating Income Expenses	-	$-5,000	$-42,000	$-20,000
Interest Expense Non Operating	-	$-3,317,000	$3,417,000	$4,170,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-78,259,000	$-35,129,000	$-31,544,000	$-41,658,000
Net Interest Income	$4,351,000	$3,312,000	$-3,417,000	$-4,170,000
Normalized Income	$-70,738,200	$-37,138,760	$-27,888,670	$-41,658,000
Net Income From Continuing And Discontinued Operation	$-78,259,000	$-35,129,000	$-31,544,000	$-41,658,000
Total Operating Income As Reported	$-72,925,000	$-68,512,000	$-27,351,000	-
Net Income Common Stockholders	$-78,259,000	$-35,129,000	$-31,544,000	$-41,658,000
Net Income	$-78,259,000	$-35,129,000	$-31,544,000	$-41,658,000
Net Income Including Noncontrolling Interests	$-78,259,000	$-35,129,000	$-31,544,000	$-41,658,000
Net Income Continuous Operations	$-78,259,000	$-35,129,000	$-31,544,000	$-41,658,000
Pretax Income	$-78,094,000	$-35,015,000	$-31,530,000	$-41,630,000
Special Income Charges	$0	$-36,861,000	$-3,907,000	$0
Operating Income	$-72,925,000	$-40,871,000	$-23,444,000	$-37,440,000
Gross Profit	$59,000	$807,000	$640,000	$14,617,000
Depreciation Amortization Depletion Income Statement	-	-	$0	$38,000
Depreciation And Amortization In Income Statement	-	-	$0	$38,000
Amortization Of Intangibles Income Statement	-	-	$0	$38,000
Net Income Discontinuous Operations	-	-	-	$0
Per Share
Diluted EPS	$-5.84	$-20.91	$-113.58	$-1063.20
Basic EPS	$-5.84	$-7.94	$-113.58	$-1063.20
Other
Tax Effect Of Unusual Items	$-1,999,200	$534,240	$-971,670	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-63,061,000	$-43,246,000	$-18,659,000	$-37,274,000
Total Unusual Items	$-9,520,000	$2,544,000	$-4,627,000	$0
Total Unusual Items Excluding Goodwill	$-9,520,000	$2,544,000	$-4,627,000	$0
Reconciled Depreciation	$344,000	$169,000	$158,000	$166,000
EBITDA (Bullshit earnings)	$-72,581,000	$-40,702,000	$-23,286,000	$-37,274,000
EBIT	$-72,925,000	$-40,871,000	$-23,444,000	$-37,440,000
Diluted Average Shares	$13,404,830	$7,496,389	$277,727	$39,182
Basic Average Shares	$13,404,830	$4,426,149	$277,727	$39,182
Diluted NI Availto Com Stockholders	$-78,259,000	$-35,129,000	$-31,544,000	$-41,658,000
Tax Provision	$165,000	$114,000	$14,000	$28,000
Restructuring And Mergern Acquisition	$0	$9,220,000	$0	-
Gain On Sale Of Security	$-9,520,000	$39,405,000	$-720,000	-
Research And Development	$50,084,000	$24,437,000	$13,784,000	$31,308,000
Selling General And Administration	$22,900,000	$17,241,000	$10,300,000	$20,711,000
Other Gand A	$8,243,000	$8,368,000	$5,770,000	$8,178,000
Salaries And Wages	$14,187,000	$8,084,000	$4,497,000	$12,457,000
Other Special Charges	-	$27,641,000	-	-
Impairment Of Capital Assets	-	$0	$3,907,000	$0
Amortization	-	-	$0	$38,000
Otherunder Preferred Stock Dividend	-	-	-	-

Fetched: 2026-06-13

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$72,547,000	$122,530,000	$-3,198,000	$-25,324,000
Total Assets	$116,458,000	$150,732,000	$20,993,000	$33,367,000
Total Non Current Assets	$11,172,000	$11,842,000	$12,598,000	$16,951,000
Other Non Current Assets	$210,000	$131,000	$131,000	$131,000
Goodwill And Other Intangible Assets	$10,502,000	$10,502,000	$10,502,000	$14,409,000
Current Assets	$105,286,000	$138,890,000	$8,395,000	$16,416,000
Other Current Assets	$6,913,000	$4,325,000	$843,000	$1,290,000
Restricted Cash	$37,000	$19,000	$1,000	$15,000
Cash Cash Equivalents And Short Term Investments	$98,336,000	$134,546,000	$7,415,000	$13,172,000
Cash And Cash Equivalents	$15,858,000	$134,546,000	$7,415,000	$13,172,000
Receivables	-	$611,000	$136,000	$1,919,000
Other Receivables	-	$611,000	$136,000	$1,919,000
Inventory	-	-	$0	$20,000
Accounts Receivable	-	-	-	$0
Other Intangible Assets	-	-	-	-
Prepaid Assets	-	-	-	-
Debt
Total Debt	$392,000	$568,000	$537,000	$19,948,000
Current Debt And Capital Lease Obligation	$392,000	$568,000	$537,000	$6,462,000
Net Debt	-	-	-	$6,244,000
Long Term Debt And Capital Lease Obligation	-	-	-	$13,486,000
Long Term Debt	-	-	-	$13,486,000
Current Debt	-	-	-	$5,930,000
Other Current Borrowings	-	-	-	$5,930,000
Liabilities
Total Liabilities Net Minority Interest	$33,409,000	$17,700,000	$13,689,000	$44,282,000
Total Non Current Liabilities Net Minority Interest	$20,469,000	$10,740,000	$9,071,000	$22,168,000
Other Non Current Liabilities	$2,035,000	$2,350,000	$3,366,000	$3,711,000
Derivative Product Liabilities	$18,000,000	$8,120,000	$5,550,000	$4,830,000
Non Current Deferred Liabilities	$434,000	$270,000	$155,000	$141,000
Non Current Deferred Taxes Liabilities	$434,000	$270,000	$155,000	$141,000
Current Liabilities	$12,940,000	$6,960,000	$4,618,000	$22,114,000
Payables And Accrued Expenses	$8,416,000	$3,149,000	$3,501,000	$12,385,000
Payables	$464,000	$610,000	$446,000	$3,390,000
Other Payable	$327,000	$327,000	-	$508,000
Accounts Payable	$137,000	$283,000	$446,000	$2,882,000
Other Current Liabilities	-	$360,000	-	$480,000
Current Deferred Liabilities	-	-	$0	$88,000
Total Tax Payable	-	-	-	-
Income Tax Payable	-	-	-	-
Equity
Common Stock Equity	$83,049,000	$133,032,000	$7,304,000	$-10,915,000
Total Equity Gross Minority Interest	$83,049,000	$133,032,000	$7,304,000	$-10,915,000
Stockholders Equity	$83,049,000	$133,032,000	$7,304,000	$-10,915,000
Gains Losses Not Affecting Retained Earnings	$68,000	$0	-	-
Other Equity Adjustments	$68,000	-	-	-
Retained Earnings	$-448,522,000	$-370,263,000	$-335,134,000	$-303,824,000
Preferred Securities Outside Stock Equity	$0	$0	$0	-
Other
Ordinary Shares Number	$18,512,757	$10,471,934	$801,746	$39,293
Share Issued	$18,512,757	$10,471,934	$801,746	$39,293
Tangible Book Value	$72,547,000	$122,530,000	$-3,198,000	$-25,324,000
Invested Capital	$83,049,000	$133,032,000	$7,304,000	$8,501,000
Working Capital	$92,346,000	$131,930,000	$3,777,000	$-5,698,000
Capital Lease Obligations	$392,000	$568,000	$537,000	$532,000
Total Capitalization	$83,049,000	$133,032,000	$7,304,000	$2,571,000
Additional Paid In Capital	$531,485,000	$503,285,000	$342,437,000	$292,909,000
Capital Stock	$18,000	$10,000	$1,000	$0
Common Stock	$18,000	$10,000	$1,000	$0
Preferred Stock	$0	$0	$0	-
Current Capital Lease Obligation	$392,000	$568,000	$537,000	$532,000
Pensionand Other Post Retirement Benefit Plans Current	$4,132,000	$2,883,000	$580,000	$2,699,000
Current Accrued Expenses	$7,952,000	$2,539,000	$3,055,000	$8,995,000
Goodwill	$10,502,000	$10,502,000	$10,502,000	$14,409,000
Net PPE	$460,000	$1,209,000	$1,965,000	$2,411,000
Accumulated Depreciation	$-253,000	$-710,000	$-542,000	$-414,000
Gross PPE	$713,000	$1,919,000	$2,507,000	$2,825,000
Leases	$575,000	$1,637,000	$2,225,000	$739,000
Machinery Furniture Equipment	$138,000	$282,000	$282,000	$336,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$82,478,000	$0	-	-
Current Deferred Revenue	-	-	$0	$88,000
Other Properties	-	-	$1,329,000	$1,750,000

Fetched: 2026-06-13

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-51,458,000	$-49,056,000	$-30,680,000	$-26,846,000
Operating Activities
Operating Cash Flow	$-51,458,000	$-49,056,000	$-30,680,000	$-26,751,000
Cash Flow From Continuing Operating Activities	$-51,458,000	$-49,056,000	$-30,680,000	$-26,751,000
Operating Gains Losses	$9,520,000	$-39,405,000	$720,000	$5,830,000
Investing Activities
Investing Cash Flow	$-81,720,000	$356,000	$-133,000	$-95,000
Cash Flow From Continuing Investing Activities	$-81,720,000	$356,000	$-133,000	$-95,000
Net Other Investing Changes	-	-	$-158,000	-
Capital Expenditure	-	-	-	$-95,000
Financing Activities
Issuance Of Capital Stock	$14,762,000	$115,625,000	$46,219,000	$34,000
Financing Cash Flow	$14,587,000	$175,849,000	$25,042,000	$-14,699,000
Cash Flow From Continuing Financing Activities	$14,587,000	$175,849,000	$25,042,000	$-14,699,000
Net Other Financing Charges	$-972,000	$-9,219,000	-	-
Net Common Stock Issuance	$14,762,000	$115,625,000	$46,219,000	$-14,772,000
Common Stock Issuance	$14,762,000	$115,625,000	$46,219,000	$34,000
Repurchase Of Capital Stock	-	-	-	$-14,806,000
Other
End Cash Position	$16,105,000	$134,696,000	$7,547,000	$13,318,000
Beginning Cash Position	$134,696,000	$7,547,000	$13,318,000	$54,863,000
Changes In Cash	$-118,591,000	$127,149,000	$-5,771,000	$-41,545,000
Proceeds From Stock Option Exercised	$797,000	$69,443,000	$67,000	$73,000
Net Investment Purchase And Sale	$-81,720,000	$0	-	-
Sale Of Investment	$32,000,000	$0	-	-
Purchase Of Investment	$-113,720,000	$0	-	-
Net Business Purchase And Sale	$0	$356,000	$0	-
Sale Of Business	$0	$356,000	$0	-
Change In Working Capital	$3,841,000	$-4,708,000	$-9,240,000	$-60,000
Change In Other Current Liabilities	$-87,000	$-88,000	$-76,000	$-9,000
Change In Payables And Accrued Expense	$6,516,000	$-1,274,000	$-11,484,000	$-4,119,000
Change In Accrued Expense	$6,662,000	$-1,111,000	$-9,048,000	$-3,632,000
Change In Payable	$-146,000	$-163,000	$-2,436,000	$-487,000
Change In Account Payable	$-146,000	$-163,000	$-2,436,000	$-487,000
Change In Prepaid Assets	$-2,588,000	$-2,871,000	$447,000	$1,082,000
Change In Receivables	$0	$-475,000	$1,783,000	$2,880,000
Other Non Cash Items	$-690,000	$24,051,000	$1,828,000	$1,389,000
Stock Based Compensation	$13,621,000	$5,852,000	$3,477,000	$7,554,000
Deferred Tax	$165,000	$114,000	$14,000	$28,000
Deferred Income Tax	$165,000	$114,000	$14,000	$28,000
Depreciation Amortization Depletion	$344,000	$169,000	$158,000	$166,000
Depreciation And Amortization	$344,000	$169,000	$158,000	$166,000
Gain Loss On Investment Securities	$9,520,000	$-39,405,000	$720,000	$4,830,000
Net Income From Continuing Operations	$-78,259,000	$-35,129,000	$-31,544,000	$-41,658,000
Repayment Of Debt	-	$0	$-21,244,000	$0
Interest Paid Supplemental Data	-	$0	$1,925,000	$2,931,000
Net Issuance Payments Of Debt	-	$0	$-21,244,000	$0
Net Long Term Debt Issuance	-	$0	$-21,244,000	$0
Long Term Debt Payments	-	$0	$-21,244,000	$0
Net PPE Purchase And Sale	-	$0	$25,000	$-95,000
Sale Of PPE	-	$0	$25,000	$0
Change In Inventory	-	$0	$20,000	$18,000
Asset Impairment Charge	-	$0	$3,907,000	$0
Purchase Of PPE	-	-	$0	$-95,000
Change In Other Working Capital	-	-	$70,000	$88,000
Changes In Account Receivables	-	-	$0	$1,060,000
Issuance Of Debt	-	-	-	$0
Income Tax Paid Supplemental Data	-	-	-	$0
Common Stock Payments	-	-	-	$-14,806,000
Long Term Debt Issuance	-	-	-	$0
Change In Other Current Assets	-	-	-	$0
Change In Tax Payable	-	-	-	$0
Change In Income Tax Payable	-	-	-	$0
Provisionand Write Offof Assets	-	-	-	$1,000,000
Purchase Of Business	-	-	-	-
Earnings Losses From Equity Investments	-	-	-	-

Fetched: 2026-06-13